Alpha Lipoic Acid in Ulcerative Colitis

This study aims at evaluating the efficacy and safety of alpha-lipoic acid as adjuvant therapy to mesalamine in patients with mild to moderate ulcerative colitis due to its effect as anti-oxidant and anti-inflammatory drug which can help to improve disease.

Inclusion Criteria: * Age ≥18 years old. * Both male and female sex. * Newly diagnosed patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline for diagnosing Ulcerative Colitis in Adults.26 * Patients treated with 5-aminosalisylic acid (mesalamine). Exclusion Criteria: * Patients with severe ulcerative colitis. * Patients with colorectal cancer. * Patients on rectal or systemic steroids. * Patients on immunosuppressants or biological therapies. * Patients with previously failed treatment with sulphasalazine. * Patients with known allergy to study medications. * History of complete or partial colectomy. * Patients with significant liver disease (fibrosis, cirrhosis, NASH, NAFLD). * Patients with other inflammatory diseases. * Patients with thyroid diseases. * Patients with arrhythmia, ischemic heart disease, and heart failure. * Patients with diabetes. * Patients on antioxidants supplement (vitamin A, C, E), selenium, co-enzyme Q. * Patients on amlodipine, levothyroxine, low strength aspirin, warfarin, atorvastatin, insulin, oral hypoglycemic, chemotherapy (drug-drug interaction).